The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic significance of blood-based multi-cancer detection in circulating tumor DNA (ctDNA): 5-year outcomes analysis.
 
Robert Swanton
Stock and Other Ownership Interests - Achilles Therapeutics; Bicycle Therapeutics; Epic Sciences; GRAIL; Relay Therapeutics
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Illumina; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Pfizer; Roche; Roche/Genentech
Consulting or Advisory Role - Achilles Therapeutics; Amgen; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; GRAIL; Illumina; Medicxi; Medicxi; Metabomed; MSD; Novartis; Roche; Sarah Cannon Research Institute
Research Funding - Archer; AstraZeneca; BMS; Boehringer Ingelheim; Ono Pharmaceutical; Personalis; Pfizer; Roche
Patents, Royalties, Other Intellectual Property - Founder of Achilles Therapeutics: a biotechnology company funded by Syncona/Wellcome Trust to target clonal Neoantigens through vaccine and cell therapy approaches; Immune checkpoint intervention in cancer (PCT/EP2016/071471),; Method for determining whether an HLA allele is lost in a tumour (PCT/GB2018/052004); Method for identifying responders to cancer treatment (PCT/GB2018/)051912); Method for treating cancer (PCT/EP2016/059401).; Method for treating cancer based on identification of clonal neo-antigens (PCT/EP2016/059401); Method of detecting tumour recurrence (PCT/GB2017/053289); Method of identifying insertion/deletion mutation targets (PCT/GB2018/051892); Method of predicting survival rates for cancer patients (PCT/GB2020/050221); Methods for lung cancer detection (PCT/US2017/028013); PCT/EP2022/077987 – Methods and systems for tumour monitoring. (Inst); PCT/EP2023/059039 – Analysis of HLA alleles transcriptional deregulation. (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca (Inst)
 
Allen Cohn
Honoraria - Amgen
Consulting or Advisory Role - AADi; EMD Serono
Expert Testimony - Department of Justice
 
Matthew Margolis
Employment - GRAIL
Stock and Other Ownership Interests - GRAIL; Illumina; Roche
Honoraria - Sanofi/Regeneron
Patents, Royalties, Other Intellectual Property - IGF1R ACTIVATION MUTATIONS AND USES THEREOF
Travel, Accommodations, Expenses - Sanofi/Regeneron
 
Earl Hubbell
Employment - GRAIL
Stock and Other Ownership Interests - Illumina
Research Funding - GRAIL
Patents, Royalties, Other Intellectual Property - GRAIL: filed patent applications
Travel, Accommodations, Expenses - GRAIL
 
Stephannie Shih
Employment - GRAIL
Stock and Other Ownership Interests - GRAIL; GRAIL (I); Illumina; Illumina (I)
 
Oliver Venn
Employment - GRAIL
Stock and Other Ownership Interests - Illumina
Patents, Royalties, Other Intellectual Property - Patents in the healthcare space
 
Michael Seiden
Employment - N Power Medicine
Leadership - Medicom Technologies; N Power Medicine
Stock and Other Ownership Interests - McKesson; Medicom Technologies; Merck; N Power Medicine
Honoraria - NeoGenomics Laboratories
Consulting or Advisory Role - GRAIL Bioscience